多孔生物陶瓷义眼座植入术矫治眼窝畸形

目的 观察多孔生物陶瓷义眼座植入术矫治眼窝畸形的临床效果。方法 将四条直肌作牵引固定眼球位置，剪断视神经，剪除角膜，彻底清除内容物，从巩膜壳颞上向鼻下剖开巩膜，把多孔生物陶瓷义眼座植入肌锥部，荷包式缝合后、前巩膜壳。结果 采用此材料和方法矫治眼窝畸形24例（24眼），均治愈。结论 多孔生物陶瓷义眼座组织相容性好，无毒副作用，是理想的眼窝充填材料。此手术方法简单，符合眼球生理运转功能，达到了眼窝整形与美容的要求及以假乱真的效果。     

眼球摘除真皮脂肪瓣移植术临床应用

眼球摘除术后眼窝塌陷,义眼不能转动,影响病人的美观,给患者带来很大痛苦。过去我们曾在手术中眼窝内放入蜡球,术后眼球可以轻度转动,但时隔不久,蜡球即脱出,使手术失败,尤其术后引起穹窿变浅,结膜囊缩窄,更使义眼按装困难。应用真皮脂肪瓣移植术于眼窝整形,效果满意,大大解除了患者的痛苦。我院自1982年11月     

巩膜壳包裹羟基磷灰石（HA）填充球制作新型可动性义眼座的手术技巧

巩膜壳包裹羟基磷灰石（ＨＡ）填充球制作新型可动性义眼座的手术技巧江西医学院第一附属医院眼科陈蔷娟，易敬林，廖洪斐口腔科万腊根人们希望在眼球摘出术后能安装一个活动美观的义眼，这样就要求眼窝内植入填充物。目前采用硅胶球、甲基丙烯酸甲酯等制作的填充球，植入...     

多孔生物陶瓷义眼座植入术矫治眼窝畸形

目的 观察多孔生物陶瓷义眼座植入术矫治眼窝畸形的临床效果。方法 将四条直肌作牵引固定眼球位置,剪断视神经,剪除角膜,彻底清除内容物,从巩膜壳顳上向鼻下剖开巩膜,把多孔生物陶瓷义眼座植入肌锥部,荷包式缝合后、前巩膜壳。结果 采用此材料和方法矫治眼窝畸形24例(24眼),均治愈。结论 多孔生物陶瓷义眼座组织相容性好,无毒副作用,是理想的眼窝充填材料。此手术方法简单,符合眼球生理运转功能,达到了眼窝整形与美容的要求及以假乱真的效果。     

多孔生物陶瓷义眼台植入术矫治眼窝畸形

目的　观察多孔磷酸钙生物陶瓷义眼台植入术矫治眼窝畸形的临床效果。方法　将四条直肌作牵引固定眼球位置 ,剪断视神经 ,剪除角膜 ,彻底清除球内容物 ,从巩膜壳颞上向鼻下剖开巩膜 ,把多孔生物陶瓷义眼台植入肌锥部 ,荷包式缝合后、前巩膜壳。结果　采用此材料和方法矫治眼窝畸形 2 4例 (2 4只眼 ) ,义眼活动良好 ,无并发症发生。结论　多孔生物陶瓷义眼台组织相容性好 ,无毒副作用 ,是理想的眼窝充填材料。此手术方法简单 ,符合眼球生理运转功能 ,达到了眼窝整形与美容的要求     

前部巩膜覆盖羟基磷灰石义眼座植入术临床观察

羟基磷灰石义眼座植入术是目前改善眼球摘除术后眼窝畸形广泛采取的治疗方法.我院对47例眼球摘除患者行前部巩膜覆盖羟基磷灰石义眼座植入术取得理想效果,报告如下.     

眼内容除去术后一次性牙托粉球充术的临床研究

目的：观察眼内容去除术后牙托粉（聚甲基丙烯酸甲酯）球眼内充填术的效果。方法：将聚甲基丙烯酸甲酯制成尺寸为：12mm-21mm大小的球体于眼内容物除去术后植入眼内，制成可转动的义眼座连体，临床用于矫正15例眼内容物除去术后的眼窝畸形患。结果：15例患术后义眼活动自如，改善了眼窝塌陷外观，随访6－36个月，未见填充球脱落， 移位及异常眼炎症反应。结论：聚甲基丙烯酸甲酯可广泛地运用于眼内充填。     

Ⅱ期羟基磷灰石义眼座眶内植入治疗眼球摘除后畸形综合征疗效观察

目的探讨对已摘除眼球后造成眼窝塌陷的病例施行Ⅱ期羟基磷灰石(hydroxyapatite,HA)义眼座眼窝植入的临床效果。方法对22例已行眼球摘除的患者,进行Ⅱ期有或无巩膜包裹羟基磷灰石义眼座植入。追踪观察3~12个月。结果植入HA义眼座球体稳定,眼眶饱满,义眼座活动度好,无严重的球体暴露脱出及移位。结论Ⅱ期羟基磷灰石义眼座眼窝内植入术后外观满意,并发症少,病程长短不限,是治疗眼球摘除术后眼窝凹陷畸形的理想方法。     

眼内容除去术后一次性牙托粉球充填术的临床研究

目的 观察眼内容去除术後牙托粉(聚甲基丙烯酸甲酯)球眼内充填术的效果。方法 将聚甲基丙烯酸甲酯制成尺寸为:12mm～21mm大小的球体于眼内容物除去术後植入眼内,制成可转动的义眼座连体,临床用于矫正15例眼内容物除去术後的眼窝畸形患者。结果 15例患者术後义眼活动自如,改善了眼窝塌陷外观,随访6～36个月,未见填充球脱落、移位及异常眼眶炎症反应。结论 聚甲基丙烯酸甲酯可广泛地运用于眼内充填。     

二期眶内羟基磷灰石填充球植入的临床应用

采用国产羟基磷灰石制成多孔网眼状结构的填充球，包埋在同种异体巩膜壳内施行二期眶内植入，临床应用于１０例无眼球，并且安不上义眼的眼窝畸形患者，获得满意而稳定的效果。     

American Uveitis Society Meeting October 30, 1995 Marriott Marquis Hotel, Atlanta, GA, USA

1 Retinal vascular occlusion and scleroderma. Tessler H, Flores-Guevara J, Goldstein D, Chicago, IL, USA. 2 MHC Class II antigen expression in ciliary body in spontaneous and experimental uveitis. Kalsow C, Zhavoronkova M, Dwyer A, Rochester, NY & Scottsville, NY, USA. 3 IL-10 in the vitreous of patients with intraocular lymphoma. Whitcup S, Solomon D, Nussenblatt R, Chan C-C, Bethesda, MD, USA 4 Iris juvenile xanthogranuloma studied by immunohistochemistry. Shields J, Shields C, Eagle R, DePotter P, Collins M, Philadelphia, PA, USA. 5 Outcomes analysis in with JRA-associated uveitis. Dana M-R, Merayo-Lloves J, Foster C, Boston MA, USA. 6 Persistent glaucoma secondary to periocular steroids. Akduman L, Conway M, Burchfield J, Kolker A, Black D, DelPriore L, Kaplan H, St. Louis, MO, USA 7 The use of itraconazole in ocular histoplasmosis Callanan D, Fish G, Dallas, TX, USA 8 Succesful treatment of macular hole secondary to sympathetic ophthalmia. Cano J, Diaz M, Navea A, Ruiz C, Castilla M. Barcelona, Spain. 9 HLA-DR2+ intermediate uveitis. Pulido J, Tang W, Han D, Mieler W. Milwaukee, WI, USA. 10 Vein occlusion in AIDS misdiagnosed as CMV retinitis. Park K, Marx J, Rao N. Los Angeles, CA, USA. 11 HIV-associated foveal hemorrhage. Crews K, Zimmerman P, Lohner S. Salt Lake City, UT, USA. 12 Cytomegalovirus papillitis in patients with AIDS. Patel S, Rutzen A, Marx J, Thach A, Chong L, Rao N, Los Angeles, CA, USA. 13 Recurrence rate of CMV retinitis following the ganciclovir implant and pars plans vitrectomy and silicone oil. Marx J, Thach A, Rao N, Chong L. Los Angeles, CA, USA.     

Cochlin及其编码基因凝血因子C同源物（COCH）在形觉剥夺性近视豚鼠眼球后极部组织的表达

目的　探讨Cochlin及其编码基因凝血因子C同源物（coagulation factor C homology，COCH）在形觉剥夺性近视（form-deprived myopia，FDM）豚鼠眼球后极部组织的表达。方法　选取3周龄的雄性健康三色豚鼠46只，随机分为2组，每组23只，饲养6周。正常对照组的双眼不予任何处理，FDM组的右眼为实验眼，左眼为自身对照，遮盖FDM组豚鼠的右眼，但不压迫右眼角膜和眼睑，保证右眼能自由瞬目。在遮盖后0周、2周、4周及6周时，分别测量两组豚鼠的屈光度、眼轴长度和角膜曲率半径；HE染色观察两组豚鼠后极部巩膜的厚度及形态变化；进行高通量蛋白质组学分析；实时荧光定量PCR检测COCH mRNA的表达量；Western blot检测Cochlin的蛋白表达水平。结果　遮盖前，两组豚鼠眼球的屈光度和眼轴长度双眼间差值（右眼-左眼）差异均无统计学意义（均为P>0.05）。遮盖后2周，相比对侧的左眼，FDM组右眼诱导出近视，眼轴相对延长；与正常对照组相比，FDM组右眼的屈光度下降，眼轴长度增加，差异均有统计学意义（均为P<0.05）。遮盖后4周和6周，FDM组的右眼相对左眼近视进一步加深，眼轴相对更加延长，近视度数和眼轴长度双眼间差值较正常对照组差异进一步加大，差异均有统计学意义（均为P<0.05）。遮盖前，遮盖后2周、4周及6周，两组豚鼠眼球的角膜曲率半径双眼间差值差异均无统计学意义（均为P>0.05）。遮盖后6周，HE染色结果显示，正常对照组右眼后极部巩膜的厚度正常，胶原纤维排列致密规则，未见断裂现象。然而FDM组右眼的后极部巩膜变薄，胶原纤维变细，变稀疏，间隙变大，且部分纤维出现断裂现象。蛋白质组学分析结果显示，正常对照组和FDM组间表达差异在1.3倍以上的蛋白共221种，其中100种上调，121种下调。其中Cochlin在FDM组豚鼠眼球后极部组织的表达量是正常对照组的3.77倍，升高趋势最明显。实时荧光定量PCR检测结果显示，遮盖后6周，在正常对照组和FDM组右眼后极部组织中，COCH mRNA的相对表达量分别为0.38±0.15和1.86±0.35。FDM组的相对表达量明显高于正常对照组，差异有统计学意义（P<0.05）。Western blot检测结果显示，在正常对照组和FDM组右眼后极部组织中，Cochlin与GAPDH的灰度比值分别为0.37±0.14和0.73±0.15。FDM组Cochlin的表达水平显著高于正常对照组，差异有统计学意义（P<0.05）。结论　FDM豚鼠眼球后极部组织中可检测到COCH mRNA和蛋白Cochlin的表达上调，提示COCH可能在FDM的发生发展中起到重要作用。     

American Uveitis Society Meeting, May 13,1995 Fort Lauderdale, FL, USA

1 Confirmation of Bartonella henselae as the cause of cat scratch related acute neuroretinitis and prospective observation to its response to oral doxycycline and rifampin. Reed B, Smith R, Dolan M, Wong M, Scales D, Department of Ophthalmology & Infectious Disease, Wilford Hall Medical Center, Lackland AFB, TX, USA. 2 Recurrence rate of CMV retinitis in patients following pars plana vitrectomy and silicone oil injection. Marx JL, Thach AB, Reingold W, Terry B, Rao NA, Chong LP. Doheny Eye Institute, Los Angeles, CA, USA. 3 A PCR based assay for the diagnosis of AIDS related VZV retinitis. Margolis T, Short G, Schwartz D, Irvine A, Martin D, Francis I. Proctor Foundation, San Francisco, CA, USA. 4 Presumptive ocular sarcoidosis. Dodds EM, Lowder CY, Meisler DM. Division of Ophthalmology, Cleveland, OH, USA. 5 Prevalence of uveitis in an outpatient juvenile arthritis clinic. Akduman L, Tychsen L, Kaplan HJ, Washington University, St. Louis, MO, USA. 6 The role of choroidal dendritic cells in the pathogenesis of experimental autoimmune uveoretinitis. Choudhury A, Padhye NS, Caspi RR, Bowers WE, University of South Carolina School of Medicine, Columbia, S.C. and The National Eye Institute, Bethesda, MD, USA.     

BOOK REVIEWS

Book reviewed in this article:
THE MYOPIAS: Basic Science and Clinical Management Brian J. Curtin. Philadelphia: Harper and Row, 1985 .
CHANDLER & GRANT'S GLAUCOMA David L. Epstein, 3rd edition, Philadelphia: Lea & Febiger, 1986, pp. 539, $118–25. ISBN 08121 0972 4 .
THYROID EYE DISEASE Devron H. Char, 1st edition, Baltimore: Williams and Wilkins, 1985, pp, 227, $134.00 .
POCKET CONSULTANT. OPHTHALMOLOGY Patrick D. Trevor-Roper. 2nd edition, Oxford: Blackwell, 1985, pp. 95, $19.50 .
THE EYE IN SYSTEMIC DISEASES Jack J. Kanski. London: Butterworths, 1986, pp. 249 $75.00 .
MICROPIGMENTATION Zwerling, Christiansen, Goldstein et al. Slack Inc, 1986, pp. 234 .
REFRACTIVE CORNEAL SURGERY Edited by Donald R. Sanders, Robert F. Hofman and James J Salz. Slack Inc, $129.00 .     

BOOK REVIEWS

Book reviewed in this article:
EYE DISEASES IN HOT CLIMATES John Sandford-Smith. Bristol: John Wright & Sons, 1986. ISBN 0 7236 0749 4. Also available in paperback .
PERIPHERAL IRIDECTOMY. SURGICAL: ARGON: YAG Arthur Lim Siew Ming. Singapore: PG Publishing, 1987, pp. 86, 100 colour illustrations, £54.00. ISBN 9971 973 86 3 .
RADIAL KERATOTOMY: SURGICAL TECHNIQUE R. F. Hofmann, R. L. Lindstrom, A. C. Neumann, J. J. Salz, G. W. Tate, S. P. Thornton. Thorofare, New Jersey: Slack, 1986, pp. 137, £67.75 .
TEXTBOOK OF GLAUCOMA M. Bruce Shields. Baltimore: Williams and Wilkins, 1987, pp. 549,£240.00. ISBN 0 683 07694 9 .
GLAUCOMA Edited by J. A. McAllister FRCS and Richard P. Wilson MD. London: Butterworths, 1986, pp. 278, £190.00. ISBN 0 407 02343 7 .
NEURO-OPHTHALMOLOGY REVIEW MANUAL Frank J. Bajandas, Lanning B. Kline. Second Edition Thorofare, New Jersey: Slack 1987, pp. 176, £A44.95. ISBN 0 943432 96 0 .
OPHTHALMIC NURSING Rosalind Stollery. Southampton: Blackwell Scientific, 1987, pp, 261, £A38.95. ISBN 0 632 01S15 2 .
ADLER'S PHYSIOLOGY OF THE EYE: CLINICAL APPLICATION Edited by Robert A. Moses and William Hart, Jr. Eighth edition. St Louis, CV. Mosby, 1987, pp, 709 .     

American Uveitis Society Meeting October 31, 1994 San Francisco,California

1 Ophthalmic manifestations of presumed rifabutin-related uveitis. Arevalo JF, Freeman WR, La Jolla, CA, USA.

2 Diagnosis of toxoplasmosis acute anterior uveitis by PCR. Cano J, Diaz M, Navee A, Maldonado M, Barcelona, Spain.

3 Neuroretinits in patients with AIDS. Berger B, Austin TX, USA.

4 Presumed varicella zoster retinitis in a pediatric patient with AIDS. El Baba F, Nachman S, Stony Brook, NY, USA.

5 ARN with hypopyon caused by EVB and herpes type VI viruses. Cano J, Diaz M, Navea A, Maldonado MJ, Barcelona, Spain.

6 CD8⁺ T-lymphocytes and ocular infections in HIV⁺ patients. Lowder CY, Butler CP, Dodds EM, Recillas-Gispert C, Cleveland, OH, USA.

7 Intravitreal foscanet for persistent CMV. Lieberman RM, Orellana J, New York, NY, USA.

8 Perfluorocarbon liquid versus air-fluid exchange during surgical repair of retinal detachment caused by cytomegalovirus retinitis in patients with AIDS. Sery T, Gomes J, Sando R, Dua H, Donoso L, Vrabec T, Philadelphia, PA, USA.

9 Endogenous ophthalmitis simulating retinoblastoma: a report of six cases. Shields J, Shields C, Eagle R, Barrett J, DePotter P, Philadelphia, PA, USA.

10 Ocular lymphoma resembling chronic postoperative endophthalmitis. Fox G, Chan CC, Whitcup SM, Nussenblatt R, Bethesda, MD, USA.

11 A phase II trial of combination chemotherapy for primary central nervous system lymphoma. Whitcup SM, Stark-Vanes V, Nussenblatt RB, Heiss H, Witte R, Bethesda, MD, USA.

12 Cancer-induced autoimmune retinopathy. Thirkill C, Sacramento, CA, USA.

13 Leukocytoclastic vasculitis. Tessler H. Chicago, IL, USA.

14 Bilateral choroidal neovascular membranes after Candida albicans chorioretinitis. Dodds E, Townsend-Pico W, Lowder CY, Lewis H, Cleveland, OH, USA.

15 An unusual complications of Toxoplasma retinochoroiditis. Gormley PD, Flaxel CJ, Pavesio CE, Conrad DK, Lightman S, London, UK.

16 Surgical removal of a choroidal neovascular membrane in sympahtetic ophthalmia. Conrad DK, McCluskey PJ, Schwartz S, Gregor Z. Lightman S, London, UK.

17 Peripheral laser scatter ablation in pars planitia. Park SE, Mieler WF, Pulido JS, Milwaukee, WI, USA.     

History of academic ophthalmology in Wroclaw,Poland in 1812-2002

The authors present the history of the Department of Ophthalmology in Wroclaw, since 1812. Special attention is paid to following professors of ophthalmology and directors of the University Eye Hospital: T.V.G. Benedict, A.T. Mitteldorf, R. Foerster, H.L. Cohn, H. Magnus, A. Groenouw, H. Willbrand; W. Uhthoff, Th. Axenfeld, G. Lenz, A. Huszcza, L. Baran, A. Bielschowsky, W. Dieter, A. Bednarski, M. Grzedzielski, L. Hirschfeld, W.J. Kapuscinski, S. Drozdowska, E. Ogielska, P. Hanczyc, M.H. Nizankowska     

复方血栓通胶囊联合氪激光治疗糖尿病性视网膜病变的疗效观察

目的观察应用复方血栓通胶囊联合氪激光治疗糖尿病性视网膜病变的疗效。方法对300例 (420只眼)随机分组、对照治疗。根据FFA造影结果分型,行视网膜次全光凝、全光凝。光凝能量、范围及光斑大小视病情而定。治疗组200例(286只眼),光凝后口服复方血栓通胶囊每日3次,每次3片,维生素C 200mg每日3 次,维生素E 100mg每日3次;而对照组100例(286只眼)口服维脑路通300mg每日3次,维生素C 200mg每日3 次,维生素E 100rng每日3次,持续服药一年。治疗前常规检查视力、眼底、FFA及眼压。结果治疗组用药后每隔半月复查视力、眼底。显效56只眼(19．5％),有效182只眼(63．6％),总有效率达83．1％。无效48只眼(16． 9％)。对照组:显效15只眼(15％),有效47只眼(47％),总有效率达62％。无效38只眼(38％)。眼底表现远不如治疗组理想,经卡方检验P<0．05,两组差异有显著性。结论复方血栓通胶囊联合氪激光治疗糖尿病视网膜病变有较好疗效,能改善视力,减少视网膜光凝量,缩短病程,提高疗效。     

The Physiologist Ewald Hering (1834–1918): Curriculum vitae

The Early vs. Late Infantile Strabismus Surgery Study Group is a group of strabismologists and orthoptists who investigate whether early or late surgery is preferable in infantile strabismus, in a non-randomized, prospective, multi-centre trial. Infants between 6 and 18 months of age will receive a standardized entry examination and then be operated either before their second anniversary in clinics A, or between their 32nd and 60th month of age in clinics B. The children will be evaluated at age six. After completion of the study, the two groups can then be compared regarding degree of binocular vision, angle of strabismus and visual acuity of the worse eye relative to the better.

Zentrum zur methodischen Betreuung von Therapiestudien, Mrs H. Dinkel, Universität Heidelberg, Im Neuenheimer Feld 305, W-69120 Heidelberg. 49.6221.565500. fax: 564195 Germany

PD Dr. H.J. Simonsz, Orthoptics &; Neuroophthalmology, Afdeling Oogheelkunde, University Hospital Dijkzigt, Dr. Molewaterplein 40, NL 3015 GD Rotterdam. 3 i. 10.4639222, ask for beeper 3394 fax: 4635105 The Netherlands PD Dr. med. G.H. Rolling, Schule für Orthoptik, Universitäts-Augenklinik, Im Neuenheimer Feld 400, W-69047 Heidelberg. 49.6221.566627/34/39 fax: 565422 Germany

Dipl.-Inform. Med. U. Haag, Universität Heidelberg, Zentrum zur methodischen Betreuung von Therapiestudien, Im Neuenheimer Feld 305, W-69120 Heidelberg. 49.6221.564192 fax: 564195 Germany

Dr. A. Deák, Augenklinik, Korányi Fasor, U-6720 Szeged. 36.62.12321/10822 fax: 22826 Hungary

Mr P. Fells, F.R.C.S., F.C. Ophth., Lower Corridor Suite, Moorfields Eye Hospital, City Road, ECIV 2PD London. 44.71.2533411 fax: 2534696 (lower corridor suite) England

Prof. R. Frosini, Istituto di Clinica Oculista dell' Universita di Firenze, Insegnamento di Ottica Fisiopatologica, Viale Morgagni 85,1–50134 Florence.

Dr. R. Gomez de Liaño, Nuñez de Balboa 81, E-28006 Madrid. 34.1.5763229/72318 Spain

Dr. O. Haugen, Orthoptic Department, Department of Ophthalmology, University of Bergen, N-3021 Bergen. Norway

Dr. med. G. Klainguti, Clinique Ophtalmique, 15 Av. de France, CH-1004 Lausanne. 41.21.9637696/250211 Switzerland

Prof.Dr. K. Krzystkowa, Ophthal. Clinic Medical Acad., 38 Copernika Str, P-31501 Krakow. 4812.223272/215210/210460/214577/220411 Poland

M.C.M.E. van Lammeren, Afdeling Orthoptie, Dienst Oogziekten, U.Z. St. Rafaël, Kapucijnenvoer 33, B-3000 Leuven.

Prof. G. Lennerstrand, Institutionen for Oftalmiatrik, Huddinge sjukhus, S-14186 Huddinge. 46.8.7461000/3854/3418 Sweden

Dr. med. H. Luka, Abt. f. Schielen, Schwachsichtigkeit und Bewegungsstörungen des Auges, Allgem. öffentl. Krankenhaus der Landeshauptstadt St. Pölten, A-3100 St. Pölten. 43.512.85597/5040 43.2742.62521 (Klappe 2869)

Dr. V. Paris, Rue de Luxembourg, 48, B-6900 Marche-en-Famenne. 32.84314749 Belgium

Dr. L.J.J.M. Prick-Wenniger, Afdeling Oogheelkunde, A.M.C., Meibergdreef 9, NL 1105 AZ Amsterdam. 31.20.5663881/6715637 The Netherlands

Prof. M.A. Quéré, 19, Rue Voltaire, F-44000 Nantes. 33.40.738370/083406 fax: 084649 France

Dr. F. Reich-d'Almeida, Rua Castilho, No 65.z:Dto, P-1200 Lissabon. 351.1520619

Dr. med. R. Weidlich, Universitäts-Augenklinik, Leninallee 8, O-4020 Halle. 37.4684.9878/81 Germany     

趋化素、肿瘤坏死因子-α与2型糖尿病视网膜病变的相关性

目的　探讨２型糖尿病视网膜病变（ｔｙｐｅ２ｄｉａｂｅｔｉｃｒｅｔｉｎｏｐａｔｈｙ,Ｔ２ＤＲ）患者血清中趋化素（ｃｈｅｍｅｒｉｎ）、肿瘤坏死因子-α（ｔｕｍｏｒｎｅｃｒｏｓｉｓｆａｃｔｏｒ-α,ＴＮＦ-α）水平及其临床意义。方法　将１６０例研究对象分为增殖性糖尿病视网膜病变（ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａ-ｂｅｔｉｃｒｅｔｉｎｏｐａｔｈｙ,ＰＤＲ）组４０例,非增殖性糖尿病视网膜病变（ｎｏｎ-ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａｂｅｔｉｃｒｅｔｉｎｏｐａｔｈｙ,ＮＰＤＲ）组４０例,单纯糖尿病（ｄｉａｂｅｔｅｓｍｅｌｌｉｔｕｓ,ＤＭ）组患者４０例以及健康对照（ｎｏｒｍａｌｃｏｎｔｒｏｌｓ,ＮＣ）组４０例。观察４组研究对象的体检指标,并检测空腹胰岛素、血糖、血脂、糖化血红蛋白及血清中ｃｈｅｍｅｒｉｎ、ＴＮＦ-α等含量。计算稳态模型评估的胰岛素抵抗指数（ｉｎｓｕｌｉｎｒｅｓｉｓｔａｎｃｅｉｎ-ｄｅｘ,ＨＯＭＡ-ＩＲ）。结果　ＤＭ组［ｃｈｅｍｅｒｉｎ为（３．８３±０．４６）ｍｇ?Ｌ－１、ＴＮＦ-α为（３７．６９±５．０７）ｎｇ?Ｌ－１］、ＮＰＤＲ组［ｃｈｅｍｅｒｉｎ为（４．６８±０．７４）ｍｇ?Ｌ－１、ＴＮＦ-α为（４０．６９±５．９０）ｎｇ?Ｌ－１］、ＰＤＲ组［ｃｈｅｍｅｒｉｎ为（５．８６±１．２９）ｍｇ?Ｌ－１、ＴＮＦ-α为（４４．１７±６．６３）ｎｇ?Ｌ－１］血清中ｃｈｅｍｅｒｉｎ、ＴＮＦ-α水平均较ＮＣ组［ｃｈｅｍｅｒｉｎ为（２．０１±０．５４）ｍｇ?Ｌ－１、ＴＮＦ-α为（２２．６０±９．７８）ｎｇ?Ｌ－１］升高,且随着ＤＲ病情的进展逐渐升高,差异均有统计学意义（均为Ｐ＜０．０５）。相关分析显示血清中ｃｈｅｍｅｒｉｎ水平与收缩压、空腹血糖、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、糖化血红蛋白、胰岛素抵抗指数均呈正相关（ｒ＝０．３３１、０．３６１、０．２５１、０．３４８、０．３０６、０．５２３、０．６４４,均为Ｐ＜０．０５）;血清中ＴＮＦ-α水平与收缩压、舒张压、空腹血糖、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、糖化血红蛋白、胰岛素抵抗指数均呈正相关（ｒ＝０．２９９、０．１５９、０．６０５、０．２６２、０．４０７、０．２８２、０．６１９、０．８０９,均为Ｐ＜０．０５）;血清中ｃｈｅｍｅｒｉｎ与ＴＮＦ-α水平呈正相关（ｒ＝０．７３８,Ｐ＜０．０５）。结论　血清中ｃｈｅｍｅｒｉｎ和ＴＮＦ-α水平的升高是Ｔ２ＤＲ的危险因子,可能共同参与了Ｔ２ＤＲ的发生发展。